Abstract: A spalling process can be employed to generate a fracture at a predetermined depth within a high quality crystalline nitride substrate, such as a bulk GaN substrate. A first crystalline conductive film layer can be separated, along the line of fracture, from the crystalline nitride substrate and subsequently bonded to a layered stack including a traditional lower-cost substrate. If the spalled surface of the first crystalline conductive film layer is exposed in the resulting structure, the structure can act as a substrate on which high quality GaN-based devices can be grown.

Abstract: A spalling process can be employed to generate a fracture at a predetermined depth within a high quality crystalline nitride substrate, such as a bulk GaN substrate. A first crystalline conductive film layer can be separated, along the line of fracture, from the crystalline nitride substrate and subsequently bonded to a layered stack including a traditional lower-cost substrate. If the spalled surface of the first crystalline conductive film layer is exposed in the resulting structure, the structure can act as a substrate on which high quality GaN-based devices can be grown.

Abstract: A buffer memory can be configured to temporarily store data in a number of queues. A processor can be configured to measure a fullness of the buffer memory. The processor can be configured to adjust thresholds and drop profiles based on a measured global resource usage for a weighted random early detection (WRED) technique with less resources than a conventional.

Abstract: A buffer memory can be configured to temporarily store data in a number of queues. A processor can be configured to measure a fullness of the buffer memory. The processor can be configured to adjust thresholds and drop profiles based on a measured global resource usage for a weighted random early detection (WRED) technique with less resources than a conventional.

Abstract: The present invention is concerned with a solid delivery form of elinogrel for the treatment of thrombosis which is notable for its multi-pH dissolution, immediate release and improved pharmacokinetic properties and stability in storage. The delivery and dosage form is a solid, oral formulation comprising: a) at least about 15% by weight elinogrel or a pharmaceutically acceptable salt thereof relative to the total weight of the overall pharmaceutical composition, and b) at least one pharmaceutically acceptable carrier. A further aspect of the present invention concerns the preparation and use of such a formulation.

Abstract: The present invention is concerned with a liquid delivery form of Elinogrel for the treatment of thrombosis which is notable for its improved dosage properties and stability. The dosage form is a liquid or a lyophilized form which is reconstituted for an injectable formulation comprising: a) at least about 3 mg/ml or up to about 15 mg/ml Elinogrel or a pharmaceutically acceptable salt thereof (post reconstitution or in liquid form), and b) at least one pharmaceutically acceptable excipient. Further aspects of the present invention concern the preparation and use of such a formulation.

Abstract: A buffer memory can be configured to temporarily store data in a number of queues. A processor can be configured to measure a fullness of the buffer memory. The processor can be configured to adjust thresholds and drop profiles based on a measured global resource usage for a weighted random early detection (WRED) technique with less resources than a conventional.

Abstract: A novel solid composition and methods for making and using the solid composition are provided. The solid composition comprises: (a) at least one active agent with a solubility of less than about 0.3 mg/ml in an aqueous solution with a pH of at most about 6.8 at a temperature of about 37° C.; and (b) a hydrophilic polymer matrix composition comprising: i) a hydrophilic polymer selected from the group consisting of METHOCEL™, POLYOX™ WSR 1105 and combinations thereof; and optionally ii) a hydrophobic polymer selected from the group consisting of Ethocel 20 premium; and (c) an alkalizer selected from the group consisting of calcium carbonate, magnesium oxide heavy and sodium bicarbonate; wherein the composition provides at least about 70% release of the active between about 7 to about 12 hours following oral administration.